|
1
|
Cooper DS, Doherty GM, Haugen BR, Kloos
RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F,
Schlumberger M, et al: Revised management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eustatia-Rutten CF, Smit JW, Romijn JA,
Van der Kleij- Corssmit EP, Pereira AM, Stokkel MP and Kievit J:
Diagnostic value of serum thyroglobulin measurements in the
follow-up of differentiated thyroid carcinoma, a structured
meta-analysis. Clin Endocrinol (Oxf). 61:61–74. 2004. View Article : Google Scholar
|
|
3
|
Toubeau M, Touzery C, Arveux P, Chaplain
G, Vaillant G, Berriolo A, Riedinger J, Boichot C, Cochet A and
Brunotte F: Predictive value for disease progression of serum
thyroglobulin levels measured in the postoperative period and after
131I ablation therapy in patients with differentiated
thyroid cancer. J Nucl Med. 45:988–994. 2004.PubMed/NCBI
|
|
4
|
Edmonds CJ, Hayes S, Kermode JC and
Thompson BD: Measurement of serum TSH and thyroid hormones in the
management of treatment of thyroid carcinoma with radioiodine. Br J
Radiol. 50:799–807. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pacini F, Ladenson PW, Schlumberger M,
Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C,
Molinaro E, et al: Radioiodine ablation of thyroid remnants after
preparation with recombinant human thyrotropin in differentiated
thyroid carcinoma: results of an international, randomized,
controlled study. J Clin Endocrinol Metab. 91:926–932. 2006.
View Article : Google Scholar
|
|
6
|
Ladenson PW, Braverman LE, Ebner SA,
Brucker-Davis F, Cooper D, Garber J, Wondisford F, Davies T,
DeGroot L, Daniels G, et al: Comparison of administration of
recombinant human thyrotropin with withdrawal of thyroid hormone
for radioactive iodine scanning in patients with thyroid carcinoma.
New Eng J Med. 337:888–896. 1997. View Article : Google Scholar
|
|
7
|
Haugen B, Pacini F, Reiners C,
Schlumberger M, Ladenson P, Sherman S, Cooper D, Graham K,
Braverman L, Skarulis M, et al: A comparison of recombinant human
thyrotropin and thyroid hormone withdrawal for the detection of
thyroid remnant cancer. J Clin Endocrinol Metab. 84:3877–3885.
1999.PubMed/NCBI
|
|
8
|
Pilli T, Brianzoni E, Capoccetti F,
Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E,
Burroni L, et al: A comparison of 1850 (50 mCi) and 3700MBq (100
mCi) 131-iodine administered doses for recombinant
thyrotropin-stimulated postoperative thyroid remnant ablation in
differentiated thyroid cancer. J Clin Endocrinol Metab.
92:3542–3546. 2007. View Article : Google Scholar
|
|
9
|
Sisson JC, Shulkin BL and Lawson S:
Increasing efficacy and safety of treatments of patients with
well-differentiated thyroid carcinoma by measuring body retentions
of 131I. J Nucl Med. 44:898–903. 2003.PubMed/NCBI
|
|
10
|
Papadimitriou D, Kottou S, Oros L, Ilias
I, Molfetas M, Tsapaki V, Perris A and Christakopoulou I:
Differentiated thyroid cancer: comparison of therapeutic iodine 131
biological elimination after discontinuation of levothyroxine
versus administration of recombinant human thyrotropin. Annals Nucl
Med. 20:63–67. 2006. View Article : Google Scholar
|
|
11
|
Remy H, Borget I, Leboulleux S, Guilabert
N, Lavielle F, Garsi J, Bournaud C, Gupta S, Schlumberger M and
Ricard M: 131I effective half-life and dosimetry in
thyroid cancer patients. J Nucl Med. 49:1445–1450. 2008. View Article : Google Scholar
|
|
12
|
Menzel C, Kranert W, Döbert N, Diehl M,
Fietz T, Nadja H, Berner U and Grünwald F: rhTSH stimulation before
radiodine therapy in thyroid cancer reduces the effective half-life
of 131I. J Nucl Med. 44:1065–1068. 2003.PubMed/NCBI
|
|
13
|
Hänscheid H, Lassmann M, Luster M, Thomas
S, Pacini F, Ceccarelli C, Ladenson P, Wahl R, Schlumberger M,
Ricard M, et al: Iodine biokinetics and dosimetry in radioiodine
therapy of thyroid cancer: procedures and results of a prospective
international controlled study of ablation after rhTSH or hormone
withdrawal. J Nucl Med. 47:648–654. 2006.
|
|
14
|
Sisson JC, Freitas J, McDougall IR, Dauer
LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ,
Wexler JA, et al: Radiation safety in the treatment of patients
with thyroid diseases by radioiodine 131I: practice
recommendations of the American Thyroid Association. Thyroid.
21:335–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dow KH, Ferrell BR and Anello C:
Quality-of-life changes in patients with thyroid cancer after
withdrawal of thyroid hormone therapy. Thyroid. 7:613–619. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haugen B, Cooper D, Emerson C, Luster M,
Maciel R, Biscolla R, Mazzaferri E, Medeiros-Neto G, Reiners C,
Robbins R, et al: Expanding indications for recombinant human TSH
in thyroid cancer. Thyroid. 18:687–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mernagh P, Campbell S, Dietlein M, Luster
M, Mazzaferri E and Weston AR: Cost-effectiveness of using
recombinant human TSH prior to radioiodine ablation for thyroid
cancer, compared with treating patients in a hypothyroid state: the
German perspective. Eur J Endocrinol. 155:405–414. 2006. View Article : Google Scholar
|
|
18
|
Borget I, Corone C, Nocaudie M, Allyn M,
Iacobelli S, Schlumberger M and De Pouvourville G: Sick leave for
follow-up control in thyroid cancer patients: comparison between
stimulation with Thyrogen and thyroid hormone withdrawal. Eur J
Endocrinol. 156:531–538. 2007. View Article : Google Scholar
|
|
19
|
Wang T, Cheung K, Mehta P, Roman S, Walker
H and Sosa J: To stimulate or withdraw? A cost-utility analysis of
recombinant human thyrotropin versus thyroxine withdrawal for
radioiodine ablation in patients with low-risk differentiated
thyroid cancer in the United States. J Clin Endocrin Metab.
96:1672–1680. 2010. View Article : Google Scholar
|
|
20
|
Rosário P, Borges M and Purisch S:
Preparation with recombinant human thyroid-stimulating hormone for
thyroid remnant ablation with 131I is associated with
lowered radiotoxicity. J Nucl Med. 49:1776–1782. 2008.PubMed/NCBI
|
|
21
|
David A, Blotta A, Bondanelli M, Rossi R,
Roti E, Braverman L, Busutti L and Uberti E: Serum thyroglobulin
concentrations and 131I whole-body scan results in
patients with differentiated thyroid carcinoma after administration
of recombinant human thyroid-stimulating hormone. J Nucl Med.
42:1470–1475. 2001.
|
|
22
|
Lippi F, Capezzone M, Angelini F, Taddei
D, Molinaro E, Pinchera A and Pacini F: Radioiodine treatment of
metastatic differentiated thyroid cancer in patients on
L-thyroxine, using recombinant human TSH. Eur J Endoc. 144:5–11.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jarzab B, Handkiewicz-Junak D, Roskosz J,
Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubieniecka B, Hasse-Lazar K,
Turska M and Zajusz A: Recombinant human TSH-aided radioiodine
treatment of advanced differentiated thyroid carcinoma: a
single-centre study of 54 patients. Eur J Nucl Med Molec Imaging.
30:1077–1086. 2003. View Article : Google Scholar
|
|
24
|
Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS,
Kim SC, Hong SJ and Shong YK: Serum thyroglobulin levels at the
time of 131I remnant ablation just after thyroidectomy
are useful for early prediction of clinical recurrence in low-risk
patients with differentiated thyroid carcinoma. J Clin Endocrin
Metab. 90:1440–1445. 2005.PubMed/NCBI
|
|
25
|
Piccardo A, Arecco F, Morbelli S, Bianchi
P, Barbera F, Finessi M, Corvisieri S, Pestarino E, Foppiani L,
Villavecchia G, Cabria M and Orlandi F: Low thyroglobulin
concentrations after thyroidectomy increase the prognostic value of
undetectable thyroglobulin levels on levo-thyroxine suppressive
treatment in low-risk differentiated thyroid cancer. J Enddocrinol
Invest. 33:83–87. 2010. View Article : Google Scholar
|
|
26
|
Karam M, Feustel PJ, Postal ES, Cheema A
and Goldfarb CR: Successful thyroid tissue ablation as defined by a
negative whole-body scan or an undetectable thyroglobulin: a
comparative study. Nucl Med Commun. 26:331–336. 2005. View Article : Google Scholar : PubMed/NCBI
|
